ERBB2 and triple-negative breast carcinoma: Luminal A (HR+/HER2− with Ki-67 <14%) was identified in 19.8% (n = 16) of patients, luminal B (HR+/HER2+ with Ki-67 ≥14%) in 34.6% (n = 28), luminal HER2 in 14.8% (n = 12), HER2-enriched in 13.6% (n = 11), and triple-negative breast cancer in 17.3% (n = 14) of the cohort.